RVTY
Updated: 23/09/2026, 15:05:50
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
No summaries found.
Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.
Revenue
$2.9B
FY 2025 · Reported
Net income
$0.2B
FY 2025 · Reported
Gross margin
N/A
FY — · Reported
Free cash flow
$0.5B
FY 2025 · Calculated
R&D intensity
7.6%
FY 2025 · Calculated
Share repurchases
$0.8B
FY 2025 · Reported
Other offerings mentioned without separate sales
Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.
Map layer
Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.
Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.
Company overview
Health science solutions provider spanning discovery, development, diagnosis; HQ Waltham, Massachusetts; products marketed in more than 160 countries
“We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure.”
Reportable segments and composition change
Life Sciences (Life Sciences Solutions, Software) and Diagnostics (Immunodiagnostics, Reproductive Health); Applied Genomics integrated into Life Sciences Solutions effective FY2025
“Beginning in fiscal year 2025, the Life Sciences segment consists of Life Sciences Solutions and Software, while the Diagnostics segment consists of Immunodiagnostics and Reproductive Health.”
Reportable segments
Two reportable segments: Life Sciences and Diagnostics
“We report our business in two segments: Life Sciences and Diagnostics.”
Two operating segments
Life Sciences (Software, Life Sciences Solutions) and Diagnostics (Immunodiagnostics, Reproductive Health)
“The increase in our Life Sciences segment revenue was driven by an increase of $35.6 million in Software revenue, partially offset by a decrease of $3.1 million in Life Sciences Solutions revenue.”
Diagnostics segment brand portfolio
Diagnostics segment offers products under numerous brands including EUROIMMUN®, IDS®, T-SPOT®, Vanadis®, ViaCord®, DELFIA™, chemagic®, NeoLSD™ and others
“Our Diagnostics segment offers additional products under various brand names, including:”
Life Sciences customer base
Pharma, biotech, CROs, academic and government institutions
“We partner with global pharmaceutical, biotech and contract research organizations, as well as academic and government institutions”
Distribution model
Products marketed primarily through own specialized sales forces; distributors used where no direct sales presence
“All of our businesses market their products and services primarily through their own specialized sales forces.”
Sales channel
Direct sales force predominant; distributors only where no direct sales force
“The Company sells products and services predominantly through its direct sales force, and the use of distributors is generally limited to geographic regions where the Company has no direct sales force.”
New Diagnostics products introduced in FY2025
FY2025 new products: NeoLSD 7 Plex MS/MS kit, Bile Acid B MSMS RUO reagents, Vanadis Core Reagent Cartridge II (Reproductive Health); T-SPOT.Flex kit, ELISA 2.0 series, IDS i20 (Immunodiagnostics)
“The NeoLSD™ 7 Plex MS/MS kit, the first commercial IVD kit for screening of MLD plus 6 lysosomal storage disorders from a single dried blood spot sample.”
Life Sciences — reagents portfolio
Broad reagent portfolio including over 750 radiochemicals, 300+ GPCR/ion channel cell line products, and BioLegend catalog of more than 35,000 SKUs
“BioLegend® catalog of more than 35,000 SKUs, incorporating a large collection of antibody conjugates and modifications”
Life Sciences — instruments portfolio
Instruments spanning liquid scintillation counting, high-content screening, plate readers, in vivo optical/CT/ultrasound imaging, and cell counting/cytometry
“The Tri-Carb®, Quantulus® GCT, and plate-based MicroBeta2® families of liquid scintillation analyzers (LSAs), and Wizard2® Gamma counters”
Segment product/service families
Life Sciences: instruments, reagents, software, subscriptions, detection/imaging technologies, extended warranties, training, services; Diagnostics: instruments, solutions, consumables, reagents, services
“The Life Sciences segment principally generates revenue from sales of instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services in the life sciences market.”
GMP-grade reagents for cell and gene therapy
GMP-produced reagents serving cell and gene therapy applications
“Cell-Vive™ T-NK Xeno-Free Serum Substitute (compliant with Good Manufacturing Practice requirements (“GMP”)), and other GMP-produced reagents. These products serve several markets, notably cell and gene therapy applications.”
Revenue by geography (in thousands)
FY2025: US $1,126,274K; China $425,060K; Germany $177,664K; UK $126,849K; Other international $1,000,204K; Total $2,856,051K
“U.S.$1,126,274 $1,097,856 $1,117,654 International: China425,060 450,007 454,426”
FY2025 segment revenue
Life Sciences $1,431.1M FY2025 (vs $1,398.6M FY2024, +2%); Diagnostics $1,424.9M FY2025 (vs $1,356.4M FY2024, +5%)
“Life Sciences segment revenue was $1,431.1 million for fiscal year 2025, as compared to $1,398.6 million for fiscal year 2024”
Segment revenue FY2025-FY2023 (in thousands)
FY2025: Life Sciences $1,431,104K; Diagnostics $1,424,947K; Total $2,856,051K (FY2024: $1,398,601K/$1,356,425K/$2,755,026K; FY2023: $1,458,192K/$1,292,379K/$2,750,571K)
“$1,431,104 $1,424,947 $2,856,051 $1,398,601 $1,356,425 $2,755,026 $1,458,192 $1,292,379 $2,750,571”
Revenue by major goods/service lines (in thousands)
FY2025: Life Sciences Solutions $1,194,728K; Software $236,376K; Immunodiagnostics $869,908K; Reproductive health $555,039K (with FY2024 and FY2023 comparatives)
“Life Sciences Solutions$1,194,728 $— $1,194,728 $1,197,802 $— $1,197,802 $1,279,903 $— $1,279,903”
FX headwinds across margins
Unfavorable FX changes reduced gross margin, both segment operating margins, and raised SG&A and R&D in FY2025
“primarily due to increased tariffs, unfavorable changes in foreign exchange rates, and product mix shift”
Sole/limited source suppliers for critical raw materials
For certain critical raw materials, key components and supplies, only a limited or single source of supply is qualified
“For certain critical raw materials, key components and supplies required for the production of some of our principal products, we have qualified only a limited or a single source of supply.”
Dependence on third-party package delivery carriers
Ships significant portion of products via UPS and Federal Express (US); TNT, UPS, DHL (Europe); UPS (Asia)
“including UPS and Federal Express in the United States; TNT, UPS and DHL in Europe; and UPS in Asia.”
Global workforce composition
~11,000 employees worldwide; ~80% based outside the US; ~4,000 covered by labor union/works' council agreements
“we employed approximately 11,000 employees on a worldwide basis. Roughly 80% of our workforce is based outside of the United States.”
Subsequent event: ACD/Labs acquisition
Acquired ACD/Labs for $72M cash plus up to $8M contingent consideration (revenue metrics through 2028); ~200 employees, Toronto-based scientific software provider, to be reported in Life Sciences segment
“the Company completed its acquisition of Advanced Chemistry Development Inc. ("ACD/Labs") for $72 million in cash paid at the closing and up to $8 million in contingent consideration”
Basis of competition
Competes on service level, price, technological innovation, operational efficiency, product differentiation, product availability, quality and reliability
“We compete on the basis of service level, price, technological innovation, operational efficiency, product differentiation, product availability, quality and reliability.”
New product launches in Life Sciences
Ongoing new product introductions across assay reagents, dyes and imaging portfolios
“New assay kits for Adeno-associated Virus Vectors (AAVs) and gene therapy applications in our range of HTRF® and AlphaLISA® reagents”
Index membership and listing
Listed on NYSE under RVTY; component of S&P 500 Index
“Our common stock is listed on the New York Stock Exchange under the symbol “RVTY” and we are a component of the S&P 500 Index.”
R&D investment increase
R&D expense $215.8M FY2025 (+10%), 7.6% of revenue, driven by new product development
“Research and development expenses for fiscal year 2025 were $215.8 million, as compared to $196.8 million for fiscal year 2024, an increase of $19.0 million, or 10%.”
Growth strategy
Strategy centered on innovation, acquisitions in both segments, AI adoption, operational excellence, disciplined capital allocation and buybacks
“Advancing the use of Artificial Intelligence (“AI”) to further strengthen our differentiated offerings and to drive internal operating efficiencies”
FY2025 tariff impact on cost of revenue
Tariffs increased cost of revenue by ~$25M in FY2025; net gross margin impact ~$20M after mitigation; mostly Europe-manufactured products sold in U.S.
“Tariffs enacted and implemented during fiscal year 2025 increased our cost of revenue by approximately $25 million. Through proactive mitigation efforts, the net impact on gross margin was approximately $20 million.”
Senior unsecured notes carrying vs fair value
Senior unsecured notes: carrying value $3,222.9M, fair value $2,963.7M at Dec 28, 2025 (FY2024: $3,151.5M / $2,765.5M)
“The Company's outstanding senior unsecured notes had an aggregate fair value of $2,963.7 million and aggregate carrying value of $3,222.9 million as of December 28, 2025.”
Senior unsecured notes repaid 2024
Interest expense declined in FY2025 due to repayment of senior unsecured notes matured September 2024
“Interest expense was lower for the fiscal year 2025 as compared to prior year primarily due to a lower debt balance as a result of the repayment of senior unsecured notes that matured in September 2024.”
Long-term growth foundation statement
Management cites product offerings, market positions, global scale, and financial strength as foundation for long-term growth, margin expansion, and cash flow
“we believe that our range of product offerings, leading market positions, global scale and financial strength provides us with a foundation for continued long-term growth, margin expansion and robust cash flow generation”
FDA and government contracting regulation
Products subject to FDA and similar foreign agency regulation; non-compliance risks include fines, shutdowns, seizures/recalls, and inability to sell products; also subject to government-contract statutes
“Some of our products are subject to regulation by the FDA and similar foreign agencies.”
Customer demand sensitivity to government funding
Customers include pharma/biotech, labs, academic institutions, public health authorities, healthcare organizations, doctors, government agencies; US funding/regulatory changes created a more cautious spending environment
“Recently announced and proposed changes in U.S. funding and regulations have created a more cautious spending environment for our customers”
Macroeconomic and geopolitical risks incl. tariffs and Ukraine conflict
Business affected by global economic/political conditions including inflation, interest rates, trade barriers/tariffs on US trading partners, and the conflict in Ukraine
“Environmental events and political changes, including trade barriers and tariffs, such as the recent tariffs announced or imposed on U.S. trading partners and retaliatory measures threatened or imposed in response, and war or other conflicts, such as the current conflict in Ukraine”
Competitor consolidation trend
Expects proportion of large competitors to increase through continued consolidation of competitors
“We expect the proportion of large competitors to increase through the continued consolidation of competitors.”
New product introduction and technological obsolescence risk
Industries characterized by rapid technological change; failure to introduce new products timely may cause market share loss and missed revenue growth targets
“We sell many of our products in industries characterized by rapid technological change, frequent new product and service introductions, and evolving customer needs and industry standards.”
China diagnostic testing policy changes pressured Diagnostics margin
China diagnostic testing policy changes drove product mix shift, contributing to Diagnostics margin decline in FY2025
“product mix shift due to China diagnostic testing policy changes”
US is the largest single geography with $1,126.3M of FY2025 revenue, ~39% of total revenue.
“U.S.$1,126,274 $1,097,856 $1,117,654”
Life Sciences segment serves pharmaceutical, biotech, CRO, academic and government customers whose research spending drives demand.
“We partner with global pharmaceutical, biotech and contract research organizations, as well as academic and government institutions”
Customer base includes pharma/biotech companies whose spending is sensitive to funding and economic conditions.
“Our customers include pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors and government agencies.”
Products regulated by FDA and similar foreign agencies; non-compliance risks include shutdown of production and recalls.
“Some of our products are subject to regulation by the FDA and similar foreign agencies.”
Tariffs enacted in FY2025 raised cost of revenue by ~$25M (net ~$20M gross margin impact), concentrated on Europe-manufactured products sold in the U.S.; mitigated via manufacturing optimization, supplier collaboration, selective pricing, and temporary cost measures.
“The majority of this impact affected products manufactured in Europe and sold in the U.S. market.”
China generated $425.1M of FY2025 revenue (~15% of total), the largest disclosed international market, creating revenue and geopolitical exposure.
“China425,060 450,007 454,426”
Cuts or freezes in government funding for healthcare and research would reduce demand and add pricing pressure.
“cuts in government funding, deficit reduction efforts or other actions that reduce or freeze the availability of government funding for healthcare and research or unfavorable changes in government regulations would likely result in a reduction in demand for our products and services”
Software line grew to $236.4M in FY2025 from $200.8M FY2024, and SaaS drives deferred revenue and unbilled receivables, indicating growing recurring revenue base.
“Software236,376 — 236,376 200,799 — 200,799 178,289 — 178,289”
Immunodiagnostics revenue rose $41.3M in FY2025, the largest contributor to Diagnostics segment growth.
“due to an increase of $41.3 million in Immunodiagnostics revenue and an increase of $27.2 million in Reproductive Health revenue”
Software revenue growth of $35.6M drove the entire Life Sciences segment increase and was the main Life Sciences growth driver in FY2025.
“driven by an increase of $35.6 million in Software revenue, partially offset by a decrease of $3.1 million in Life Sciences Solutions revenue”
Single or limited source qualification for critical raw materials creates production dependency risk.
“we have qualified only a limited or a single source of supply”
GMP reagents and AAV/gene therapy assay kits position the company to benefit from cell and gene therapy research growth.
“These products serve several markets, notably cell and gene therapy applications.”
China diagnostic testing policy changes caused a product mix shift that reduced Diagnostics segment operating margin by 194 bps in FY2025.
“product mix shift due to China diagnostic testing policy changes”
Reproductive Health revenue increased $27.2M in FY2025, contributing to the 5% Diagnostics segment growth.
“an increase of $27.2 million in Reproductive Health revenue”
Revenue depends on direct sales force, with distributors limited to regions lacking direct coverage.
“The Company sells products and services predominantly through its direct sales force, and the use of distributors is generally limited to geographic regions where the Company has no direct sales force.”
Recent tariffs on US trading partners and retaliation could interfere with supply chain, customers and activities.
“trade barriers and tariffs, such as the recent tariffs announced or imposed on U.S. trading partners and retaliatory measures threatened or imposed in response”
Unfavorable FX changes reduced consolidated gross margin by 104 bps alongside tariffs and product mix, and hurt both segments' operating margins and SG&A/R&D in FY2025; FX contributed ~1% favorable revenue.
“primarily due to increased tariffs, unfavorable changes in foreign exchange rates, and product mix shift”
Company strategy explicitly targets AI to strengthen differentiated offerings and internal efficiency.
“Advancing the use of Artificial Intelligence (“AI”) to further strengthen our differentiated offerings and to drive internal operating efficiencies”
Significant portion of shipments depend on independent package delivery providers; disruption or price increases would interfere with shipping and raise costs.
“If one or more of the package delivery or import/export providers experiences a significant disruption in services or institutes a significant price increase, we may have to seek alternative providers”
Post-year-end acquisition adds scientific software for analytical characterization and molecular design, to be recognized in Life Sciences segment.
“ACD/Labs is based in Toronto, Canada, has approximately 200 employees, and is a provider of scientific software solutions that support analytical characterization and molecular design”
Pillar Two minimum 15% corporate tax rate is a disclosed factor affecting effective tax rate and quarterly results.
“the enactment by countries of the Organization for Economic Cooperation and Development (OECD) Base Erosion and Profit Shifting Pillar Two, which would impose a minimum corporate income tax rate of at least 15%”
China's diagnostic testing policy changes shifted product mix and compressed Diagnostics margins, a regulatory demand/mix risk to the segment.
“primarily due to increased tariffs, unfavorable changes in foreign exchange rates, and product mix shift due to China diagnostic testing policy changes”
FY2025 restructuring of $55.9M (vs $17.5M in FY2024) covered workforce reductions affecting ~5% of employees and facility consolidations to streamline operations and contain costs.
“restructuring and other costs, net, which was $55.9 million for fiscal year 2025, as compared to $17.5 million for fiscal year 2024”
See which prediction-market events move RVTY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay
Zacks Investment Research • STOCK • 14/05/2026, 15:01:11
Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 13/05/2026, 17:10:48
RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution
Zacks Investment Research • STOCK • 05/05/2026, 13:41:07
Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 05/05/2026, 13:01:13
Revvity (RVTY) Q1 Earnings and Revenues Top Estimates
Zacks Investment Research • STOCK • 05/05/2026, 10:45:27
Revvity to Report Q1 Earnings: What's in Store for the Stock?
Zacks Investment Research • STOCK • 04/05/2026, 11:50:59
RVTY Unveils Signals BioDesign for Faster Molecular Cloning & R&D Data
Zacks Investment Research • STOCK • 13/04/2026, 14:00:22
Revvity Gains on Diagnostics Strength, Faces China Headwinds
Zacks Investment Research • STOCK • 06/04/2026, 18:06:06
Revvity, Inc. (RVTY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Seeking Alpha • STOCK • 10/03/2026, 19:20:15
Why Is Revvity (RVTY) Down 5.1% Since Last Earnings Report?
Zacks Investment Research • STOCK • 04/03/2026, 13:31:08
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
Zacks Investment Research • STOCK • 04/03/2026, 11:21:10
Revvity, Inc. (RVTY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Seeking Alpha • STOCK • 03/03/2026, 18:12:16
